INCY - Incyte Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
66.57
+0.01 (+0.02%)
At close: 4:00PM EDT

66.57 0.00 (0.00%)
After hours: 5:07PM EDT

Stock chart is not supported by your current browser
Previous Close66.56
Open66.06
Bid65.51 x 800
Ask67.91 x 800
Day's Range66.00 - 66.98
52 Week Range60.23 - 140.11
Volume726,898
Avg. Volume2,613,495
Market Cap14.111B
Beta1.15
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Is Agenus Inc. (AGEN) a Buy?
    Motley Fool12 days ago

    Is Agenus Inc. (AGEN) a Buy?

    This cancer-focused biotech will take plenty of shots on goal in the years ahead.

  • Big Peninsula biotech buyout means happy returns for Kleiner Perkins, other VCs
    American City Business Journals13 days ago

    Big Peninsula biotech buyout means happy returns for Kleiner Perkins, other VCs

    Legendary venture capital firm Kleiner Perkins Caufield & Byers bought into Redwood City's ARMO BioSciences Inc. in December 2012 when Series A shares sold for $1. It stuck with the company into a January IPO at $17 and now with a $50-per-share buyout by Eli Lilly & Co.

  • Insider Buying Roundup: Elon Musk Buys Tesla (TSLA) Shares After Earnings Call Backlash
    Insider Monkey16 days ago

    Insider Buying Roundup: Elon Musk Buys Tesla (TSLA) Shares After Earnings Call Backlash

    Tesla Motors Inc (NASDAQ:TSLA) CEO Elon Musk has made amends with investors of his company after a poorly handled earnings call last week sent shares of the electric automaker tumbling. Musk bought 33,000 Tesla shares on Monday in a series of purchases that lifted his indirect ownership of Tesla to just under 33.64 million shares. […]

  • Thomson Reuters StreetEvents17 days ago

    Edited Transcript of INCY earnings conference call or presentation 1-May-18 12:00pm GMT

    Q1 2018 Incyte Corp Earnings Call

  • Incyte (INCY) Incurs Loss in Q1, Revenues Miss Estimates
    Zacks22 days ago

    Incyte (INCY) Incurs Loss in Q1, Revenues Miss Estimates

    Incyte (INCY) reported disappointing results for the first quarter wherein the company reported a loss against expectation of earnings and sales too missed estimates.

  • Barrons.com23 days ago

    Biotech: Better Luck Next Time

    For the full year, the company reaffirmed revenue forecasts for its chemotherapy treatment Jakafi and leukemia drug Iclusig, and also increased its estimated non-GAAP research and development costs. It still expects trial results for its graft-versus-host treatment ruxolitinib in the first half of the year.  Elsewhere, Regeneron is down 1.9% to $297.86 after Guggenheim's Adnan Butt downgraded the company to Neutral from Buy, following product reports from partner Sanofi (SNY) last week that may "foreshadow a slower-than-forecast ramp." He also warns that cholesterol drug Praluent and arthritis drug Kevzara may not see near-term accelerated growth, while chemotherapy treatment Eylea could face new competition--hence his decision to downgrade the shares until there is "greater pipeline progress." He thinks the stock's fair value is $362.

  • Incyte (INCY) Reports A Loss in Q1
    Zacks23 days ago

    Incyte (INCY) Reports A Loss in Q1

    Incyte reported a loss in the first quarter while sales also beat estimates.

  • Drug Stocks Q1 Earnings to Watch on May 1: PFE, MRK & More
    Zacks24 days ago

    Drug Stocks Q1 Earnings to Watch on May 1: PFE, MRK & More

    Four pharma/biotech companies are set to release earnings report on May 1. Let's take a look into how the companies are placed ahead of the upcoming results.

  • Investopedia24 days ago

    Google's Alphabet Median Pay Close To $200K

    Alphabet Inc. ( GOOG), Google's parent company, paid its employees nearly $200,000 last year, placing it in fourth place in terms of median compensation among S&P 500 Index companies that disclose pay. Citing Alphabet, the Wall Street Journal reported that in 2017 it had median pay packages of more than $197,000, which was 18% below Facebook Inc. ( FB) where the median salary was $240,000 in 2017. Excluding the two, which are embroiled in a talent war with other technology companies, the median salary for companies in the S&P 500 was $69,205, noted the Wall Street Journal.

  • Should You Sell Incyte (INCY) Before Earnings?
    Zacks24 days ago

    Should You Sell Incyte (INCY) Before Earnings?

    Incyte (INCY) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to earnings beat.

  • Can Jafaki Help Incyte (INCY) Beat Earnings Estimates in Q1?
    Zacks27 days ago

    Can Jafaki Help Incyte (INCY) Beat Earnings Estimates in Q1?

    Incyte (INCY) is likely to beat on earnings when it reports first-quarter results on May 1 driven by strong Jakafi sales.

  • Lessons to Learn From April's Biotech Blowups
    Motley Fool29 days ago

    Lessons to Learn From April's Biotech Blowups

    Three biotechs reported devastating clinical trial failures this month. Here are the important takeaways.

  • TheStreet.com29 days ago

    Eli Lilly CEO Expresses Confidence in New Rheumatoid Arthritis Drug

    rheumatoid arthritis drug baricitinib, Eli Lilly chairman and CEO David Ricks on an earnings call Tuesday expressed confidence in the benefit-risk profile of both doses of the treatment. The advisory panel recommended that the FDA approve the 2-mg dose of baricitinib, but not the 4-mg dose for the proposed indication based on the adequacy of the safety and benefit-risk profiles. "While we are pleased that the FDA's arthritis advisory committee supported the efficacy of both 2 mg and 4 mg of baricitinib in RA and 2 mg overall, we are disappointed that the committee did not recommend approval of the 4-mg dose," Ricks said.

  • MarketWatchlast month

    Eli Lilly, Incyte shares drop after mixed FDA drug recommendation

    Eli Lilly & Co. shares dropped nearly 3% in premarket trade Tuesday after the company's rheumatoid arthritis therapy baricitinib was recommended for Food and Drug Administration approval at the 2-mg dose, but not the 4-mg dose. Incyte Corp. , a partner on the drug, had its shares drop nearly 5% premarket. The recommendation, made by the FDA's arthritis advisory committee late Monday, was based on concerns about the 4-mg dose's safety and risks relative to its benefits.

  • Eli Lilly's earnings beat expectations, and its improved outlook overcomes regulatory setback
    CNBClast month

    Eli Lilly's earnings beat expectations, and its improved outlook overcomes regulatory setback

    Eli Lilly shares gain after the drugmaker beats first-quarter earnings expectations.

  • Reuterslast month

    FDA panel against higher dose of Lilly-Incyte arthritis drug

    An arthritis drug developed by Eli Lilly & Co and Incyte Corp should not be approved at a 4-milligram dose, advisers to the U.S. FDA voted on Monday, in a setback to the drugmakers that were counting on the treatment as a future blockbuster.

  • 3 Biotech Stocks With Major Catalysts Incoming
    Motley Foollast month

    3 Biotech Stocks With Major Catalysts Incoming

    Highly anticipated events expected in the weeks ahead could set these three biotechs up for long-term success.

  • Eli Lilly's Blockbuster Resurrection Story Has Holes
    Bloomberglast month

    Eli Lilly's Blockbuster Resurrection Story Has Holes

    Its arthritis drug's new lease on FDA life apparently comes with conditions.

  • MarketWatchlast month

    Gilead shares drop on FDA concerns with similar Eli Lilly, Incyte drug

    Gilead Sciences Inc. shares dropped 2.1% in moderate Thursday trade after a Food and Drug Administration briefing document raised safety questions about a similar Eli Lilly & Co. and Incyte Corp. drug. ...

  • MarketWatchlast month

    Eli Lilly, Incyte shares fall after FDA cites issues with rheumatoid arthritis drug

    Eli Lilly & Co. shares fell 1.8% premarket and Incyte Corp. shares dropped 4.5% premarket on Thursday after a Food and Drug Administration briefing document raised issues with their rheumatoid arthritis drug baricitinib. The drug will go up before a FDA arthritis advisory committee meeting on Monday. The FDA often follows an advisory committee's recommendation, though there are exceptions.

  • Reuterslast month

    FDA staff cites safety issues for Lilly, Incyte's rheumatoid arthritis drug

    The U.S. Food and Drug Administration staff on Thursday flagged concerns about potentially fatal blood clots from higher doses of Eli Lilly and Co and Incyte Corp's rheumatoid arthritis drug. An independent ...

  • Motley Foollast month

    What Incyte's Phase 3 Fail Means for Immuno-Oncology

    Incyte’s phase 3 Epacadostat trial wasn’t so hot, and stocks all across biotech are feeling the burn.

  • NewLink Shares Bite The Dust After Merck-Incyte Melanoma Failure
    Investor's Business Dailylast month

    NewLink Shares Bite The Dust After Merck-Incyte Melanoma Failure

    NewLink toppled Monday after it scrapped a late-stage study of its immuno-oncology drug in combination with drugs from Merck and Bristol.

  • Motley Foollast month

    What's Next for Incyte?

    With a key pipeline drug nixed, Incyte has a few more question marks on the horizon than it did before.

  • MarketWatchlast month

    NewLink shares fall on late-stage trial changes

    NewLink Genetics Corp. shares fell as much as 15% in premarket trade Monday after the company said it won't proceed as planned with a late-stage trial of its indoximod for advanced melanoma. The company ...